Patents by Inventor Francisco Xavier Talamas

Francisco Xavier Talamas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180298026
    Abstract: Compounds of the formula I or II: wherein X, m, Ar, R1 and R2 are as defined herein. The subject compounds are useful for treatment of IRAK-mediated conditions.
    Type: Application
    Filed: June 18, 2018
    Publication date: October 18, 2018
    Inventors: Nidhl Arora, Shaoqing Chen, Johannes Cornelius Hermann, Andreas Kuglstatter, Sharada Shenvi Labadie, Ciara Jeou Jen Lin, Matthew C. Lucas, Amy Geraldine Moore, Eva Papp, Francisco Xavier Talamas, Jutta Wanner, Yansheng Zhai
  • Patent number: 10023589
    Abstract: Compounds of the formula I or II: wherein X, m, Ar, R1 and R2 are as defined herein. The subject compounds are useful for treatment of IRAK-mediated conditions.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: July 17, 2018
    Assignees: Hoffmann-La Roche Inc., Roche Palo Alto LLC
    Inventors: Nidhi Arora, Shaoqing Chen, Johannes Cornelius Hermann, Andreas Kuglstatter, Sharada Shenvi Labadie, Clara Jeou Jen Lin, Matthew C. Lucas, Amy Geraldine Moore, Eva Papp, Francisco Xavier Talamas, Jutta Wanner, Yansheng Zhai
  • Patent number: 9708357
    Abstract: The present invention relates to the use of 3?-fluoro, 4?-azido nucleoside phosphoramidate prodrug derivatives of formula I wherein the symbols are as defined in the specification, to pharmaceutically acceptable salts thereof, and to pharmaceutical compositions containing such compounds for the treatment of HCV.
    Type: Grant
    Filed: December 17, 2012
    Date of Patent: July 18, 2017
    Assignee: Riboscience, LLC
    Inventors: Mark Smith, Francisco Xavier Talamas, Jing Zhang, Zhuming Zhang
  • Publication number: 20160207936
    Abstract: Compounds of the formula I or II: wherein X, m, Ar, R1 and R2 are as defined herein. The subject compounds are useful for treatment of IRAK-mediated conditions.
    Type: Application
    Filed: December 18, 2015
    Publication date: July 21, 2016
    Inventors: Nidhi Arora, Shaoqing Chen, Johannes Cornelius Hermann, Andreas Kuglstatter, Sharada Shenvi Labadie, Ciara Jeou Jen Lin, Matthew C. Lucas, Amy Geraldine Moore, Eva Papp, Francisco Xavier Talamas, Jutta Wanner, Yansheng Zhai
  • Patent number: 9255110
    Abstract: Compounds of the formula I or II: wherein X, m, Ar, R1 and R2 are as defined herein. The subject compounds are useful for treatment of IRAK-mediated conditions.
    Type: Grant
    Filed: April 2, 2014
    Date of Patent: February 9, 2016
    Assignees: ROCHE PALO ALTO LLC, HOFFMANN-LA ROCHE INC.
    Inventors: Nidhi Arora, Shaoqing Chen, Johannes Cornelius Hermann, Andreas Kuglstatter, Sharada Shenvi Labadie, Clara Jeou Jen Lin, Matthew C. Lucas, Amy Geraldine Moore, Eva Papp, Francisco Xavier Talamas, Jutta Wanner, Yansheng Zhai
  • Publication number: 20140369959
    Abstract: The present invention relates to the use of nucleoside derivatives of formula (I) wherein the symbols are as the specification, and of pharmaceutically acceptable salts thereof and to pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: December 17, 2012
    Publication date: December 18, 2014
    Inventors: Mark Smith, Francisco Xavier Talamas, Jing Zhang, Zhuming Zhang
  • Publication number: 20140303149
    Abstract: Compounds of the formula I or II: wherein X, m, Ar, R1 and R2 are as defined herein. The subject compounds are useful for treatment of IRAK-mediated conditions.
    Type: Application
    Filed: April 2, 2014
    Publication date: October 9, 2014
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Nidhi Arora, Shaoqing Chen, Johannes Cornelius Hermann, Andreas Kuglstatter, Sharada Shenvi Labadie, Clara Jeou Jen Lin, Matthew C. Lucas, Amy Geraldine Moore, Eva Papp, Francisco Xavier Talamas, Jutta Wanner, Yansheng Zhai
  • Patent number: 8734777
    Abstract: Compounds having the formula (I) wherein R1, R2, R3 and X are as defined herein are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for treating an HCV infection and inhibiting HCV replication.
    Type: Grant
    Filed: August 10, 2011
    Date of Patent: May 27, 2014
    Assignee: Roche Palo Alto LLC
    Inventors: Jim Li, Francisco Xavier Talamas
  • Publication number: 20130209397
    Abstract: Compounds having the formula (I) wherein R1, R2, R3 and X are as defined herein are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for treating an HCV infection and inhibiting HCV replication.
    Type: Application
    Filed: August 10, 2011
    Publication date: August 15, 2013
    Applicant: Roche Palo Alto LLC
    Inventors: Jim Li, Francisco Xavier Talamas
  • Patent number: 8487103
    Abstract: Method for treating an HCV infection and inhibiting HCV replication with a compound of formula I wherein R1, R2, R3, R4, X1, X2, X3 and X4 and as defined herein
    Type: Grant
    Filed: August 18, 2011
    Date of Patent: July 16, 2013
    Assignee: Roche Palo Alto LLC
    Inventors: Javier de Vicente Fidalgo, Jim Li, Ryan Craig Schoenfeld, Francisco Xavier Talamas, Joshua Paul Gergely Taygerly
  • Patent number: 8329712
    Abstract: Compounds having the formula I wherein R1, R2, R3 and X are as defined herein are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for treating an HCV infection and inhibiting HCV replication.
    Type: Grant
    Filed: July 6, 2011
    Date of Patent: December 11, 2012
    Assignee: Roche Palo Alto LLC
    Inventors: Ryan Craig Schoenfeld, Francisco Xavier Talamas, Leanna Renee Staben
  • Patent number: 8273773
    Abstract: Compounds having the formula I wherein R1, R2, R3, R4a, R4b, R4c, R5, R6, R9 and n are as defined herein are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for treating an HCV infection and inhibiting HCV replication.
    Type: Grant
    Filed: July 22, 2009
    Date of Patent: September 25, 2012
    Assignee: Roche Palo Alto LLC
    Inventors: Kenneth Albert Brameld, David Scott Carter, Elbert Chin, Javier de Vicente Fidalgo, Jim Li, Ryan Craig Schoenfeld, Eric Brian Sjogren, Francisco Xavier Talamas
  • Patent number: 8232271
    Abstract: Compounds having the formula I wherein R1, R2, R3a, R3b, R3c, R4, R5 and p are as defined herein are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for treating an HCV infection and inhibiting HCV replication.
    Type: Grant
    Filed: October 30, 2009
    Date of Patent: July 31, 2012
    Assignee: Roche Palo Alto LLC
    Inventors: Jim Li, Alfred Sui-Ting Lui, Kristen Lynn McCaleb, Francisco Xavier Talamas
  • Patent number: 8178547
    Abstract: Compounds having the formula I wherein A, R1, R2, R3, R4a, R4b, R4c, R5, R6, R7a, R7b, Ar1, Rc, Rd, Re, Rf, X, n and p are as defined herein are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for treating an HCV infection and inhibiting HCV replication.
    Type: Grant
    Filed: December 14, 2009
    Date of Patent: May 15, 2012
    Assignee: Roche Palo Alto LLC
    Inventors: Sandra Steiner, Jim Li, Ryan Craig Schoenfeld, Francisco Xavier Talamas
  • Patent number: 8168792
    Abstract: Compounds having the formula A-R wherein A is a heteroaryl and R is Ia, Ib or Ic and wherein A, R, R1, R2a, R2b, R2c, R3a, R3b, R4, R5, R6, Ra, Rb, Rc, Rd, X, X1, X2 and n are as are as defined herein are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for treating an HCV infection and inhibiting HCV replication.
    Type: Grant
    Filed: March 5, 2010
    Date of Patent: May 1, 2012
    Assignee: Roche Palo Alto LLC
    Inventors: Sarah C. Abbot, Alfred Sui-Ting Lui, Jim Li, Francisco Xavier Talamas
  • Patent number: 8158631
    Abstract: Compounds having the formula I wherein R1, R2, R3, R4, and R5 are as defined herein are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for treating an HCV infection and inhibiting HCV replication.
    Type: Grant
    Filed: June 24, 2010
    Date of Patent: April 17, 2012
    Assignee: Roche Palo Alto LLC
    Inventors: Elbert Chin, Javier de Vicente Fidalgo, Jim Li, Alfred Sui-Ting Lui, Kristen Lynn McCaleb, Ryan Craig Schoenfeld, Francisco Xavier Talamas
  • Patent number: 8158803
    Abstract: Compounds having the formula I wherein R1, R2, R3, R4, R5a, R5b, R5c and R6 are as defined herein are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for treating an HCV infection and inhibiting HCV replication.
    Type: Grant
    Filed: April 23, 2010
    Date of Patent: April 17, 2012
    Assignee: Roche Palo Alto LLC
    Inventors: Eun Kyung Lee, Ryan Craig Schoenfeld, Francisco Xavier Talamas
  • Publication number: 20120015962
    Abstract: Compounds of the formula I or II: wherein X, m, Ar, R1 and R2 are as defined herein. The subject compounds are useful for treatment of IRAK-mediated conditions.
    Type: Application
    Filed: July 12, 2011
    Publication date: January 19, 2012
    Inventors: Nidhi Arora, Shaoqing Chen, Johannes Cornelius Hermann, Adreas Kuglstatter, Sharada Shenvi Labadie, Clara Jeou Jen Lin, Matthew C. Lucas, Amy Geraldine Moore, Eva Papp, Francisco Xavier Talamas, Jutta Wanner, Yansheng Zhai
  • Publication number: 20120009144
    Abstract: Compounds having the formula I wherein R1, R2, R3 and X are as defined herein are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for treating an HCV infection and inhibiting HCV replication.
    Type: Application
    Filed: July 6, 2011
    Publication date: January 12, 2012
    Applicant: Roche Palo Alto LLC
    Inventors: Ryan Craig Schoenfeld, Francisco Xavier Talamas, Leanna Renee Staben
  • Publication number: 20110300103
    Abstract: Method for treating an HCV infection and inhibiting HCV replication with a compound of formula I wherein R1, R2, R3, R4, X1, X2, X3 and X4 and as defined herein
    Type: Application
    Filed: August 18, 2011
    Publication date: December 8, 2011
    Applicant: Roche Palo Alto LLC
    Inventors: Javier de Vicente Fidalgo, Jim Li, Ryan Craig Schoenfeld, Francisco Xavier Talamas, Joshua Paul Gergely Taygerly